CTOs on the Move

Intarcia

www.intarcia.com

 
We operate with a “No Analog” mindset—continually pushing boundaries, navigating new terrain and unleashing fresh thinking. We are committed to seeking better outcomes which compels us to ask questions that have not been asked before or remain unresolved. We are driven by a desire to create meaningful impact across business, health and society to ease the burden on people living with chronic diseases. Intarcia is a rapidly emerging biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease. Our cross-disciplinary teams include forward-thinking scientists and entrepreneurs collaborating in a fast-paced environment redefining the future of medicine.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.intarcia.com
  • One Marina Park Drive 13 Floor
    Boston, MA USA 02210
  • Phone: 617.936.2500

Executives

Name Title Contact Details
Nalin Narayanam
Chief Information Security Officer Profile
Anders Vinther
Global Head of Technical Operations Profile
Andrew Palan
Chief Information Officer Profile
Andrew Palan
‎Chief Information Officer Profile

Funding

Intarcia raised $215M on 09/15/2016
Intarcia raised $206M on 01/02/2017

Similar Companies

Gyroscope Therapeutics

Gyroscope Therapeutics is a clinical-stage gene therapy company developing gene therapy beyond rare disease to treat diseases of the eye that cause vision loss and blindness. The company was acquired by Novartis, a leading global medicines company, in February 2022.

Singulex

Singulex is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DMS Health Technologies

DMS Provides Mobile, Interim, and Fixed-Site Diagnostic Imaging Services and Medical Equipment Sales, Service, Parts, Rentals.

Access Bio Inc

Access Bio Inc is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enzymerx

Enzymerx is a Paramus, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.